EU AI Act Amendments Get Green Light From Parliament Committees In Latest Vote

The European Commission’s hotly debated AI Act proposal is a step closer to becoming law after 13 amendments were voted in by members of the European Parliament. The landmark legislation is set to have an enormous impact on all AI products, including many medical devices.

EU Vote
• Source: Shutterstock

A wave of claps erupted in the European Parliament this morning after members voted by a “large majority” in favor of 13 amendments to the Artificial Intelligence (AI) Act, meaning the controversial regulatory proposal is one step closer to becoming law. This development is one that is set to have large implications for the medtech sector, as once the AI Act is adopted it will set new compliance requirements for many medical devices (more below.)

In total, 84 members of the Internal Market and Consumer Protection (IMCO) and the Civil Liberties, Justice and Home Affairs...

More from Europe

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By 

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Sofinnova And NVIDIA Partner To ‘Supercharge’ Computation For European Startups

 

European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.

More from Geography